So far, the combination of ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) has been approved by the US Food and Drug Administration (FDA) for clinical use in mTBI patients (15). This evidence concerns the gene GFAP and concussion.